Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
About this item
Full title
Author / Creator
Tolaney, Sara M , Barry, William T , Dang, Chau T , Yardley, Denise A , Moy, Beverly , Marcom, P. Kelly , Albain, Kathy S , Rugo, Hope S , Ellis, Matthew , Shapira, Iuliana , Wolff, Antonio C , Carey, Lisa A , Overmoyer, Beth A , Partridge, Ann H , Guo, Hao , Hudis, Clifford A , Krop, Ian E , Burstein, Harold J and Winer, Eric P
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
A multicenter single-group trial suggests that adjuvant therapy with paclitaxel plus trastuzumab lowers the risk of relapse in women with small HER2-positive breast cancers.
Overexpression of the human epidermal growth factor receptor type 2 (HER2) occurs in approximately 15 to 20% of invasive breast cancers and was historically associated with...
Alternative Titles
Full title
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4313867
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4313867
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1406281
